GALT
GALT
NASDAQ · Biotechnology

Galectin Therapeutics Inc

$2.80
-0.03 (-1.06%)
As of Feb 8, 2:06 PM ET ·
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 42.71M 37.98M 43.70M
Net Income -4,071,906 -4,331,190 -4,441,576
EPS
Profit Margin -9.5% -11.4% -10.2%
Rev Growth +12.9% +2.3% +21.5%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 74.62M 82.00M 80.44M
Total Equity 85.11M 74.58M 75.96M
D/E Ratio 0.88 1.10 1.06
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA -6,278,520 -5,337,134 -5,924,921
Free Cash Flow -4,174,488 -3,744,064 -5,531,991